Vaidya A B, Antarkar D S, Doshi J C, Bhatt A D, Ramesh V, Vora P V, Perissond D, Baxi A J, Kale P M
Ciba Research Centre, Goregaon, Bombay.
J Postgrad Med. 1996 Oct-Dec;42(4):105-8.
Picrorhiza kurroa (Pk), a known hepatoprotective plant, was studied in experimental and clinical situtations. The standardization of active principles--Picroside 1 and 2 was done with High Performance Liquid Chromatography. Picroside 1 ranged from 2.72 to 2.88 mg/capsule and picroside 2 from 5.50 to 6.00 mg/capsule. In the galactosamine-induced liver injury in rats, Pk at a dose of 200 mg/kg p.o. showed a significant reduction (p < 0.05) in liver lipid content, GOT and GPT. In a randomised, double-blind placebo controlled trial in patients diagnosed to have acute viral hepatitis (HBsAg negative), Pk root powder 375 mg three times a day was given for 2 weeks (n = 15) or a matching placebo (n = 18) was given. Difference in values of bilirubin, SGOT and SGPT was significant between placebo and Pk groups. The time in days required for total serum bilirubin to drop to average value of 2.5 mg% was 75.9 days in placebo as against 27.44 days in Pk group. The present study has shown a biological plausability of efficacy of Pk as supported by clinical trial in viral hepatitis, hepatoprotection in animal model and an approach for standardizing extracts based on picroside content.
胡黄连是一种已知具有肝脏保护作用的植物，已在实验和临床环境中进行了研究。采用高效液相色谱法对活性成分——胡黄连苷1和胡黄连苷2进行了标准化。胡黄连苷1的含量为每粒胶囊2.72至2.88毫克，胡黄连苷2的含量为每粒胶囊5.50至6.00毫克。在大鼠半乳糖胺诱导的肝损伤模型中，口服剂量为200毫克/千克的胡黄连显著降低了肝脏脂质含量、谷草转氨酶（GOT）和谷丙转氨酶（GPT）（p < 0.05）。在一项针对诊断为急性病毒性肝炎（乙肝表面抗原阴性）患者的随机、双盲、安慰剂对照试验中，给予15名患者每日三次、每次375毫克的胡黄连根粉，持续2周，另18名患者给予匹配的安慰剂。安慰剂组和胡黄连组之间胆红素、谷草转氨酶和谷丙转氨酶值的差异具有统计学意义。安慰剂组血清总胆红素降至平均2.5毫克%所需的天数为75.9天，而胡黄连组为27.44天。本研究表明，胡黄连的疗效具有生物学合理性，这得到了病毒性肝炎临床试验、动物模型肝脏保护作用以及基于胡黄连苷含量标准化提取物方法的支持。
